Orakl Oncology is a Paris-based TechBio company, a spin-off from the Gustave Roussy cancer institute, building an AI-powered drug-development platform that combines one of the largest biobanks of patient tumor avatars (organoids) with deep clinical and omics data and machine learning to predict how individual patients will respond to new cancer… - View it on GitHub